Greenwood Capital Associates LLC decreased its position in Amgen, Inc. (NASDAQ:AMGN) by 6.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 15,566 shares of the medical research company’s stock after selling 1,005 shares during the period. Greenwood Capital Associates LLC’s holdings in Amgen were worth $2,707,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Baker Ellis Asset Management LLC bought a new position in shares of Amgen in the third quarter worth approximately $108,000. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the last quarter. Phocas Financial Corp. bought a new position in shares of Amgen in the second quarter worth approximately $110,000. Omnia Family Wealth LLC grew its holdings in shares of Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the last quarter. Finally, Salem Investment Counselors Inc. grew its holdings in shares of Amgen by 4.7% in the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after purchasing an additional 36 shares during the last quarter. Hedge funds and other institutional investors own 79.61% of the company’s stock.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.19% of the company’s stock.
Amgen, Inc. (AMGN) opened at $188.24 on Friday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $136,726.67, a price-to-earnings ratio of 73.25, a price-to-earnings-growth ratio of 2.33 and a beta of 1.37. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.89 EPS. equities research analysts forecast that Amgen, Inc. will post 13.24 EPS for the current fiscal year.
Amgen declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.80%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 205.45%.
AMGN has been the topic of several recent analyst reports. Vetr cut shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a report on Wednesday, January 3rd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $189.00 price target on shares of Amgen in a research note on Wednesday, January 24th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Cann reaffirmed a “buy” rating and issued a $205.00 price target on shares of Amgen in a research note on Thursday, November 30th. Finally, Cowen reaffirmed a “buy” rating and issued a $204.00 price target on shares of Amgen in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Amgen presently has an average rating of “Hold” and an average target price of $191.72.
WARNING: “Amgen, Inc. (AMGN) Stake Lessened by Greenwood Capital Associates LLC” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/03/17/amgen-inc-amgn-stake-lessened-by-greenwood-capital-associates-llc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.